What is Tardive Dyskinesia?
Tardive Dyskinesia is an involuntary neurological movement disorder caused by the use of dopamine receptor blocking drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions.
How many people are affected by Tardive Dyskinesia?
· Tardive Dyskinesia is estimated to affect at least 500,000 people in the US.
· Tardive Dyskinesia occurrence is estimated to be 2–5% annually, and the condition occurs in 15–30%of those who receive long-term treatment with antipsychotic drugs [APDs].
· Women are at higher risk of developing Tardive Dyskinesia than men especially in middle-aged to senior patients.
Request for free sample pages @ Tardive Dyskinesia Market Share
What is used for treatment of Tardive Dyskinesia?
Tardive Dyskinesia Treatment initially consists of discontinuing the neuroleptic drug as soon as involuntary facial, neck, trunk, or extremity movements are identified in people taking neuroleptic drugs if this is felt to be safe psychiatrically.
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are two FDA approved drugs used for Tardive Dyskinesia treatment. Tetrabenazine is often useful for symptomatic treatment of Tardive Dyskinesia and is currently available for use in the US. However, it carries the risk of causing or aggravating depression. Other experimental drugs are being tested to reduce or eliminate the Tardive Dyskinesia symptoms.
How will Tardive Dyskinesia Market change in upcoming years?
Tardive Dyskinesia market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment regimens.
Tardive Dyskinesia pipeline is very narrow. There is major lacks of effective targeted treatments for Tardive Dyskinesia with the current treatment options being focused on treating the Tardive Dyskinesia symptoms. This poses as a huge unmet medical need for treatment of Tardive Dyskinesia and opens a great market opportunity for companies.
Key players involved in Tardive Dyskinesia Treatment Market are SOM Biotech (SOM3355), Contera Pharma (JM-010), and many others.
Request for free sample pages @ Tardive Dyskinesia Market Trends and Forecast